Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Neuroone Medical Technologies (NMTC) Gross Margin (2020 - 2026)

Neuroone Medical Technologies filings provide 11 years of Gross Margin readings, the most recent being 53.81% for Q1 2026.

  • On a quarterly basis, Gross Margin fell 180.0% to 53.81% in Q1 2026 year-over-year; TTM through Mar 2026 was 54.5%, a 31.0% increase, with the full-year FY2025 number at 56.51%, up 2525.0% from a year prior.
  • Gross Margin hit 53.81% in Q1 2026 for Neuroone Medical Technologies, down from 54.2% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 58.85% in Q4 2024 to a low of 99.01% in Q1 2022.
  • Median Gross Margin over the past 5 years was 34.13% (2024), compared with a mean of 23.15%.
  • Biggest five-year swings in Gross Margin: surged 10577bps in 2023 and later plummeted -465bps in 2025.
  • Neuroone Medical Technologies' Gross Margin stood at 10.74% in 2022, then soared by 354bps to 27.24% in 2023, then soared by 116bps to 58.85% in 2024, then fell by -8bps to 54.2% in 2025, then decreased by -1bps to 53.81% in 2026.
  • The last three reported values for Gross Margin were 53.81% (Q1 2026), 54.2% (Q4 2025), and 55.77% (Q3 2025) per Business Quant data.